Evaluation of PXL065 - Deuterium-Stabilized (R)-Pioglitazone in NASH Patients: a Phase 2 randomized placebo-controlled trial (DESTINY-1).

[1]  F. Underwood,et al.  The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. , 2022, The lancet. Gastroenterology & hepatology.

[2]  A. Sanyal,et al.  Breakthroughs in therapies for NASH and remaining challenges. , 2022, Journal of hepatology.

[3]  D. Moller,et al.  Therapeutic potential of deuterium‐stabilized (R)‐pioglitazone—PXL065—for X‐linked adrenoleukodystrophy , 2022, Journal of inherited metabolic disease.

[4]  N. Lanthier,et al.  A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH. , 2021, The New England journal of medicine.

[5]  L. Birnbaumer,et al.  Therapeutic targeting of hepatic ACSL4 ameliorates NASH in mice , 2021, Hepatology.

[6]  Ming‐Lung Yu,et al.  First-in-Asian double-blind randomized trial to assess the efficacy and safety of insulin sensitizer in nonalcoholic steatohepatitis patients , 2021, Hepatology International.

[7]  Z. Younossi,et al.  The Burden of Nonalcoholic Fatty Liver Disease in Asia, Middle East and North Africa: Data from Global Burden of Disease 2009-2019. , 2021, Journal of hepatology.

[8]  V. Wong,et al.  Non-alcoholic fatty liver disease , 2021, The Lancet.

[9]  Ajit S. Divakaruni,et al.  Deuterium‐Stabilized (R)‐Pioglitazone (PXL065) Is Responsible for Pioglitazone Efficacy in NASH yet Exhibits Little to No PPARγ Activity , 2021, Hepatology communications.

[10]  O. Cummings,et al.  Relationship of ELF and PIIINP With Liver Histology and Response to Vitamin E or Pioglitazone in the PIVENS Trial , 2021, Hepatology communications.

[11]  M. Pompili,et al.  Pioglitazone and bariatric surgery are the most effective treatments for non‐alcoholic steatohepatitis: A hierarchical network meta‐analysis , 2020, Diabetes, obesity & metabolism.

[12]  F. Anania,et al.  Nonalcoholic Steatohepatitis: Current Thinking From the Division of Hepatology and Nutrition at the Food and Drug Administration , 2020, Hepatology.

[13]  K. Cusi,et al.  A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis. , 2020, The New England journal of medicine.

[14]  Kathryn J Fowler,et al.  Change in MRI-PDFF and Histologic Response in Patients with Nonalcoholic Steatohepatitis: A Systematic Review and Meta-Analysis. , 2020, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[15]  F. Tacke,et al.  Differential effects of selective- and pan-PPAR agonists on experimental steatohepatitis and hepatic macrophages. , 2020, Journal of hepatology.

[16]  K. Cusi,et al.  Change in hepatic fat content measured by MRI does not predict treatment-induced histological improvement of steatohepatitis. , 2020, Journal of hepatology.

[17]  Manfred von der Ohe,et al.  Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial , 2019, The Lancet.

[18]  B. Neuschwander‐Tetri,et al.  Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial , 2019, The Lancet.

[19]  G. Latunde-Dada,et al.  Programmed Cell-Death by Ferroptosis: Antioxidants as Mitigators , 2019, International journal of molecular sciences.

[20]  K. Cusi,et al.  From NASH to diabetes and from diabetes to NASH: Mechanisms and treatment options , 2019, JHEP reports.

[21]  H. Nakano,et al.  Hepatic ferroptosis plays an important role as the trigger for initiating inflammation in nonalcoholic steatohepatitis , 2019, Cell Death & Disease.

[22]  K. Cusi,et al.  Role of Vitamin E for Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes: A Randomized Controlled Trial , 2019, Diabetes Care.

[23]  V. Ratziu.  A critical review of endpoints for non-cirrhotic NASH therapeutic trials. , 2018, Journal of hepatology.

[24]  Xianlin Han,et al.  A role for long-chain acyl-CoA synthetase-4 (ACSL4) in diet-induced phospholipid remodeling and obesity-associated adipocyte dysfunction , 2018, Molecular metabolism.

[25]  Michael Charlton,et al.  The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases , 2018, Hepatology.

[26]  Charlotte R. Feddersen,et al.  The mitochondrial pyruvate carrier mediates high fat diet-induced increases in hepatic TCA cycle capacity , 2017, Molecular metabolism.

[27]  J. Schaffer,et al.  Targeting the mitochondrial pyruvate carrier attenuates fibrosis in a mouse model of nonalcoholic steatohepatitis , 2017, Hepatology.

[28]  M. Jensen,et al.  How to Measure Adipose Tissue Insulin Sensitivity , 2017, The Journal of clinical endocrinology and metabolism.

[29]  E. Paschetta,et al.  Pioglitazone for advanced fibrosis in nonalcoholic steatohepatitis: New evidence, new challenges , 2016, Hepatology.

[30]  J. Hardies,et al.  Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus , 2016, Annals of Internal Medicine.

[31]  H. Tilg,et al.  EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. , 2016, Journal of hepatology.

[32]  James E. Nelson,et al.  Iron overload results in hepatic oxidative stress, immune cell activation, and hepatocellular ballooning injury, leading to nonalcoholic steatohepatitis in genetically obese mice. , 2016, American journal of physiology. Gastrointestinal and liver physiology.

[33]  B. Neuschwander‐Tetri,et al.  Practice patterns in NAFLD and NASH: real life differs from published guidelines , 2016, Therapeutic advances in gastroenterology.

[34]  W. Zou,et al.  An Insulin‐Sensitizing Thiazolidinedione, Which Minimally Activates PPARγ, Does Not Cause Bone Loss , 2015, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[35]  Ajit S. Divakaruni,et al.  Thiazolidinediones are acute, specific inhibitors of the mitochondrial pyruvate carrier , 2013, Proceedings of the National Academy of Sciences.

[36]  R. Loomba,et al.  Meta‐analysis: pioglitazone improves liver histology and fibrosis in patients with non‐alcoholic steatohepatitis , 2012, Alimentary pharmacology & therapeutics.

[37]  Y. Barak,et al.  Role for PPARγ in obesity‐induced hepatic steatosis as determined by hepatocyte‐ and macrophage‐specific conditional knockouts , 2011, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[38]  B. Neuschwander‐Tetri,et al.  Therapeutic trials in nonalcoholic steatohepatitis: Insulin sensitizers and related methodological issues , 2010, Hepatology.

[39]  J. Hardies,et al.  Pioglitazone in the treatment of NASH: the role of adiponectin , 2010, Alimentary pharmacology & therapeutics.

[40]  B. Neuschwander‐Tetri,et al.  Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. , 2010, The New England journal of medicine.

[41]  P. Giral,et al.  Long‐term efficacy of rosiglitazone in nonalcoholic steatohepatitis: Results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial , 2009, Hepatology.

[42]  L. J. Hardies,et al.  Importance of changes in adipose tissue insulin resistance to histological response during thiazolidinedione treatment of patients with nonalcoholic steatohepatitis , 2009, Hepatology.

[43]  G. Aithal,et al.  Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. , 2008, Gastroenterology.

[44]  Philippe Giral,et al.  Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial. , 2008, Gastroenterology.

[45]  Y. Wan,et al.  PPAR-γ regulates osteoclastogenesis in mice , 2007, Nature Network Boston.

[46]  A. Hamsten,et al.  Genes Involved in Fatty Acid Partitioning and Binding, Lipolysis, Monocyte/Macrophage Recruitment, and Inflammation Are Overexpressed in the Human Fatty Liver of Insulin-Resistant Subjects , 2007, Diabetes.

[47]  T. Therneau,et al.  The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD , 2007, Hepatology.

[48]  J. Hardies,et al.  A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. , 2006, The New England journal of medicine.

[49]  J. Hoofnagle,et al.  Changes in serum adipokine levels during pioglitazone treatment for nonalcoholic steatohepatitis: relationship to histological improvement. , 2006, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[50]  O. Cummings,et al.  Design and validation of a histological scoring system for nonalcoholic fatty liver disease , 2005, Hepatology.

[51]  J. Hoofnagle,et al.  A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis , 2004, Hepatology.

[52]  D. Crabb,et al.  Antidiabetic thiazolidinediones inhibit collagen synthesis and hepatic stellate cell activation in vivo and in vitro. , 2002, Gastroenterology.

[53]  S. O’Rahilly,et al.  Induction of Adipocyte Complement-Related Protein of 30 Kilodaltons by PPARγ Agonists: A Potential Mechanism of Insulin Sensitization. , 2002, Endocrinology.

[54]  N. Enomoto,et al.  Pioglitazone prevents early-phase hepatic fibrogenesis caused by carbon tetrachloride. , 2002, Biochemical and biophysical research communications.

[55]  T. M. Lewin,et al.  Expression and Characterization of Recombinant Rat Acyl-CoA Synthetases 1, 4, and 5 , 2001, The Journal of Biological Chemistry.

[56]  S. Aronoff,et al.  Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group. , 2000, Diabetes care.

[57]  D. Crabb,et al.  Peroxisome proliferator‐activated receptor γ transcriptional regulation is involved in platelet‐derived growth factor–induced proliferation of human hepatic stellate cells , 2000 .

[58]  J. Lehmann,et al.  Peroxisome proliferator-activated receptor-gamma activation by thiazolidinediones induces adipogenesis in bone marrow stromal cells. , 1996, Molecular pharmacology.

[59]  J. Lehmann,et al.  An Antidiabetic Thiazolidinedione Is a High Affinity Ligand for Peroxisome Proliferator-activated Receptor γ (PPARγ) (*) , 1995, The Journal of Biological Chemistry.

[60]  R. Loomba,et al.  Noninvasive Tests (NITs) in the Management of Nonalcoholic Steatohepatitis (NASH) , 2020 .

[61]  Bumseok Kim,et al.  Ferroptosis affects the progression of non-alcoholic steatohepatitis via the modulation of lipid peroxidation-mediated cell death in mice. , 2019, The American journal of pathology.

[62]  A. Walch,et al.  ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition. , 2017, Nature chemical biology.